Mereo BioPharma (‘Mereo’) was incorporated in March 2015 and is dual-listed on London Stock Exchange’s AIM market (MPH) and NASDAQ (MREO).
The company acquired a portfolio of three product candidates from Novartis in July 2015 and a fourth product from AstraZeneca in October 2017.
In April 2019, Mereo merged with OncoMed, a Nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing novel oncology products.
The combination has strengthened the balance sheet, broadened the shareholder base and further diversified the product portfolio. With the merger, Mereo has added two additional clinical stage oncology programs to its pipeline.